miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting
Christine Esau(Ionis Pharmaceuticals (United States)), Brett P. Monia(Ionis Pharmaceuticals (United States)), Sheri Booten(Ionis Pharmaceuticals (United States)), Robert A. McKay(Ionis Pharmaceuticals (United States)), Susan Murray(Ionis Pharmaceuticals (United States)), Amuthakannan Subramaniam(Ionis Pharmaceuticals (United States)), Bridget Lollo(Ionis Pharmaceuticals (United States)), Scott Davis(Unknown), Michael Pear(Ionis Pharmaceuticals (United States)), Stephanie Propp(Ionis Pharmaceuticals (United States)), C. Frank Bennett(Pennsylvania State University), Xing Yu(Ionis Pharmaceuticals (United States)), Sanjay K. Pandey(Ionis Pharmaceuticals (United States)), Mark J. Graham(Ionis Pharmaceuticals (United States)), Lynnetta M. Watts(Ionis Pharmaceuticals (United States)), Susan M. Freier(Ionis Pharmaceuticals (United States)), Sanjay Bhanot(Ionis Pharmaceuticals (United States))
Cited by 2,061
Related Papers
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
|Cancer Cell|2004|1.9k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k
Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis
|Hepatology|2007|1k
Evaluation of 2‘-modified oligonucleotides containing 2‘-deoxy gaps as antisense inhibitors of gene expression
|Journal of Biological Chemistry|1993|770
Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis
|New England Journal of Medicine|2014|621